Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

BridgeBio

Explore full profile

Focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform

Palo Alto, United StatesFounded 2014Biotech & Life Sciences
Valuation $17B Market cap · Aug/2026
Revenue $961M Latest reported FY

At a glance

Founded
2014
Headquarters
Palo Alto, United States
Listing
IPO 2019
Sector
Biotech & Life Sciences
Power Law
Decacorn$10B+ valuation tierThoroughbred$100M+ revenue

Knowledge graph

News, research, reports and resources connected to this company by Dealroom
News Lionsbridge takes $704K stake in BridgeBio Pharma as analysts turn bullish Sep 2, 2026 News Rinascera launches with initial funding to tackle rare skin diseases Jul 17, 2026 News BridgeBio lands $1B from Sixth Street, KKR to fuel drug launches Jul 1, 2026

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later11 investors entered at this stage

Talent

Book a demo to see the people
Employees mapped 1,019 incl. 2 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 31 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇺🇸 United States96.1%
🇨🇭 Switzerland2.3%
🇳🇱 Netherlands1.1%
🇬🇧 United Kingdom0.4%
🇦🇷 Argentina0.2%
5 countries shown
Web traffic by country
46K monthly visits
across markets
🇺🇸 United States66.1%
🇨🇦 Canada12.2%
🇮🇳 India7.6%
🇬🇧 United Kingdom4.1%
🇸🇪 Sweden3.5%
Top 5 markets shown

Patents

Estimated portfolio value
$88M

61 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Investments and acquisitions

Disclosed deals where BridgeBio was the backer or acquirer, 2014–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

7 deals across BridgeBio's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        Where BridgeBio deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        BridgeBio's portfolio, mapped.

        Stage
        Period
        7 of 7 deals

        Market sentiment

        Posts on X, past 7 days

        An AI-synthesised read of the highest-engagement posts about BridgeBio on X, ranked by likes and reposts, corporate channels excluded.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See BridgeBio on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles